Anticoagulation therapy is the mainstay of stroke prevention in atrial fibrillation (AF). Evidence for its clinical value is already well established. In the era of novel oral anticoagulation (NOAC) therapy, regular checkup for international normalized ratio (INR) and dose adjustment are no more necessary. However, vitamin K antagonist (VKA), as a traditional oral anticoagulation agent, still plays a role in certain circumstances. The INR level significantly impacts the effectiveness and safety of VKA. Most international AF guidelines suggest dose adjustment of VKA to keep INR level between 2 and 3 to reach an optimal clinical result.[1](#joa312186-bib-0001){ref-type="ref"} In addition, keeping time in therapeutic range (TTR) of VKA more than 60% is very important in not only four major randomized control trials (RCTs) of NOAC, but also guidelines recommendations.[1](#joa312186-bib-0001){ref-type="ref"} However, in real world practice, INR is difficult to be kept in the ideal therapeutic range, especially in the Asia region.[1](#joa312186-bib-0001){ref-type="ref"} The cause of poor TTR includes drug adherence, social economic status, education level, comorbidities, etc. Among all the comorbidities, cardiovascular disease that needs antiplatelet agents is even more challenging. In this issue, Park et al published an article telling how cardiovascular disease and antiplatelet therapy impact the use of VKA and the TTR.[2](#joa312186-bib-0002){ref-type="ref"}

This study is a multicenter noninterventional prospective study. They included 877 patients from 20 tertiary hospitals in the Republic of Korea. All patients were with AF, older than 20 years and put on VKA. Among them, antiplatelet therapy was prescribed in 229 patients with cardiovascular disease, making the regimen become VKA plus antiplatelet. Other patients, without cardiovascular disease, took VKA alone. The CHA2DS2‐VAS scores were similar in both groups. The HAS‐BLED was higher in the VKA plus antiplatelet group than the VKA alone group (1.9 ± 0.7 vs 1.3 ± 0.5, *P* \< 0.001). After 1 year of follow‐up, the VKA plus antiplatelet group were with significantly lower INR level (1.66 ± 0.8 vs 1.94 ± 0.94, *P* = 0.0005) than the VKA alone group. In addition, in the group of VKA plus antiplatelet, more patients discontinued VKA during the observation period (28.8% vs 24.2%, *P* = 0.045). However, both groups had poor achievement of TTR \> 60% (33.9% vs 35.3%, *P* = 0.74) and similar bleeding events (8.1% vs 8.4%, *P* = 0.93).

This study raised the critical issue of lower INR level and poor TTR performance of VKA in real world clinical practice, especially in the Asia countries. For patients who need both anticoagulation and antiplatelet therapy, the severity of VKA under‐dosing was even greater. The bleeding event rates were similar in both groups, which means that under‐dosing of VKA was not driven by bleeding episodes, but by physician\'s decision. Because of higher HAS‐BLED score in the anticoagulation plus antiplatelet group, the physician may concern the increased bleeding risk and decide to use lower dose of VKA when combined with antiplatelet agent. However, this combination resulted in lower INR level. Based on the fact that antiplatelet therapy offers little benefit to AF related thromboembolism, the lower INR level, of course, could not adequately prevent AF‐related thromboembolism.[3](#joa312186-bib-0003){ref-type="ref"} In addition, this study also pointed out another major issue in real world practice, poor TTR performance (\>60%). Only about one‐third patients in both groups could reach the target of TTR \>60%. This finding also reflected the high risk of thromboembolism events in both groups because of uncontrolled INR level when using inadequate dose VKA and the high‐discontinue rate of VKA (more than 25%) by physician\'s decision.

Why did the Korean physicians keep lower INR level in AF patients who also need antiplatelet therapy? Inadequate dosage of anticoagulant is very common in Asia countries. There are several reasons for this critical clinical issue. First, the physicians concern the safety (such as bleeding events) more than efficacy (such as prevention of ischemic stroke) when using oral anticoagulant. As the physicians have to face the complications and side effects from the medical treatment, they could not enjoy the success or patients' feedback from ischemic stroke prevention. The situation is also common in the era of NOAC. Even without the indications to dose adjustment, Asia physicians usually use the lower dose of NOAC. Second, Asia people seem to have higher bleeding rate than Western people when using oral anticoagulant. All four NOAC RCTs demonstrated this important finding of racial difference.[1](#joa312186-bib-0001){ref-type="ref"} Therefore, the Japanese guideline set up the lower INR target level (1.6‐2.6) of VKA.[4](#joa312186-bib-0004){ref-type="ref"} Many physicians around the Asia area may agree this concept, even the newer Asia guidelines all recommend INR level to be kept between 2 and 3.[1](#joa312186-bib-0001){ref-type="ref"} Third, patient preference is also a common reason why physician uses the lower dose of oral anticoagulant, especially when the shared decision making (SDM) plays a more important role in the communication between the physician and the patient. In this SDM model, connecting evidence‐based medicine to patient‐centered communication skills may achieve optimal patient care.[5](#joa312186-bib-0005){ref-type="ref"} Finally, the bleeding rate is significantly increased when combined with VKA and antiplatelet agent. The physicians hope to reduce the bleeding complications, so they use the lower dose of VKA and keep lower INR level. These concerns result in lower INR level and poor TTR performance and may increase the thromboembolism risk of AF patients.

In conclusion, the study in this issue gives us an alert that physician\'s concern may cause inadvertently inadequate anticoagulation in AF patients with cardiovascular disease. Such behavior may leave patients in a higher risk of thromboembolic events. Since all the Asia guidelines recommend optimal INR level of VKA and the standard dose of NOAC for AF patients, the physicians should give anticoagulant based on evidences, rather than by their preference.
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